<DOC>
	<DOCNO>NCT00150631</DOCNO>
	<brief_summary>The present study examine healthy , normotensive subject 18 36 year age whose parent essential hypertension . The subject receive treatment either AT1-antagonist candesartan cilexetil , 16 mg daily placebo one year . Then , treatment withdrawn subject follow 10 year determine treatment able either prevent delay development hypertension . The primary objective determine whether pharmacological treatment angiotensin receptor blocker able restrain delay progression hypertension . Secondary objective investigate whether long-term effect blood pressure related effect treatment renal haemodynamic function , leave ventricle mass .</brief_summary>
	<brief_title>Danish Hypertension Prevention Project - DHYPP</brief_title>
	<detailed_description>Essential hypertension , major health problem worldwide , disease generally consider require life-long treatment . However , evidence suggest hypertension cause specific phenotypic change cause combination genetic environmental factor . Thus , principle , hypertension could prevent prevention phenotypic change . Animal data indicate early treatment block renin-angiotensin system long-term effect treatment withdrawal . The present human study test whether early treatment ( AT1- antagonist ) able persistent effect stop treatment . This monocenter , double-blind , randomize , placebo-controlled study healthy , normotensive ( consultation diastolic blood pressure 2 visit &lt; 85 mmHg ) subject 18 36 year age whose parent essential hypertension . The primary objective determine whether pharmacological treatment angiotensin receptor blocker able restrain delay progression hypertension . Secondary objective investigate whether long-term effect blood pressure related effect treatment renal haemodynamic function , leave ventricle mass . Subjects recruit use hospital register identify person receive indication essential hypertension , age may child appropriate age . These person mail ask child partner also hypertensive , ask permission contact child . The diagnosis hypertension parent check follow evaluation physician treat . One hundred subject randomly assign one two treatment group : placebo ; candesartan cilexetil , 16 mg , daily . Before inclusion 12 month treatment glomerular filtration rate , renal vascular resistance , echocardiography 24-hour blood pressure monitoring perform . Subjects evaluate 0.5 , 1 , 2 , 4 , 6 10 month ensure compliance control blood pressure . After 12-months treatment , 24-hour blood pressure monitoring perform scheduled manner 10-year period . The primary effect parameter 24-hour blood pressure measure 10 year withdrawal treatment . Interim analyse make 1 , 2 5 year independent data committee . Secondary effect parameter number antihypertensive treatment 2 , 5 10 year withdrawal , well effect treatment renal vascular resistance leave ventricular mass . A substudy compare renal haemodynamics genetic profil subject person normotensive parent .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>1 . Both parent essential hypertension 2 . Age 18 36 year 3 . Caucasians 4 . Diastolic blood pressure le 85 mmHg inclusion time 5 . Female participant use orale anticonceptives ot intrauterine device 1 . Clinical biochemically sign disease kidney , liver , endocrine organ 2 . Diastolic blood pressure 85 mmHg inclusion time 3 . Pregnancy pregnancy wish 4 . Daily medication , except orale anticoncetives</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Prevention</keyword>
	<keyword>Offspring</keyword>
	<keyword>Prevent delay development hypertension</keyword>
</DOC>